{"log_id": 7437657293018963881, "direction": 0, "words_result_num": 37, "words_result": [{"probability": {"variance": 0.003155, "average": 0.966169, "min": 0.783366}, "location": {"width": 827, "top": 113, "height": 44, "left": 225}, "words": "由于作用机制导致的药效动为学效应,本品可能会引起高血压、低钾血症和体液潴留。临"}, {"probability": {"variance": 0.006806, "average": 0.979625, "min": 0.461548}, "location": {"width": 870, "top": 160, "height": 46, "left": 183}, "words": "床最常见的不良反应是外周水肿、低钾血症、高血压和尿路感染。其他重要的不良反应包括心"}, {"probability": {"variance": 0.00296, "average": 0.980138, "min": 0.750572}, "location": {"width": 871, "top": 210, "height": 44, "left": 185}, "words": "脏疾病、肝脏毒性、骨折和过敏性肺泡炎。通常,盐皮质激素不良反应经处理后可以得到有效"}, {"probability": {"variance": 0.000132, "average": 0.991952, "min": 0.947395}, "location": {"width": 722, "top": 260, "height": 42, "left": 187}, "words": "的控制。联合应用皮质类固醇能够降低这些药物不良反应的发生率和严重程度"}, {"probability": {"variance": 2e-06, "average": 0.998543, "min": 0.996367}, "location": {"width": 88, "top": 368, "height": 26, "left": 189}, "words": "临床试验"}, {"probability": {"variance": 0.001406, "average": 0.984603, "min": 0.809806}, "location": {"width": 827, "top": 400, "height": 44, "left": 233}, "words": "由于临床试验的条件各异,不同药物的临床试验中观察到的不良反应发生率没有直接可比"}, {"probability": {"variance": 0.000594, "average": 0.990148, "min": 0.880363}, "location": {"width": 491, "top": 454, "height": 35, "left": 190}, "words": "性,也无法反映临床实践中观察到的不良反应发生率"}, {"probability": {"variance": 0.00994, "average": 0.964429, "min": 0.533385}, "location": {"width": 827, "top": 493, "height": 43, "left": 234}, "words": "在两项随机、安慰剂对照、多中心临床试验(研究生和研究2)中,招募了正在使用促性"}, {"probability": {"variance": 0.005924, "average": 0.972333, "min": 0.538133}, "location": {"width": 874, "top": 540, "height": 42, "left": 191}, "words": "腺激素释放激素(GnRH)治疗或既往接受过睾丸切除术的转移性去势抵抗性前列腺癌患者既"}, {"probability": {"variance": 0.018117, "average": 0.925468, "min": 0.44808}, "location": {"width": 862, "top": 588, "height": 43, "left": 193}, "words": "往接受过化疗或未接受过化疗,治疗组患者每天服用本品1000mg,每月1次合并泼尼松5mg"}, {"probability": {"variance": 0.006427, "average": 0.959837, "min": 0.711242}, "location": {"width": 559, "top": 639, "height": 37, "left": 195}, "words": "每日2次。对照组服用安慰剂,合并泼尼松5mg,每日2次"}, {"probability": {"variance": 0.021682, "average": 0.945164, "min": 0.393594}, "location": {"width": 826, "top": 679, "height": 43, "left": 239}, "words": "这两项随机临床试验报告的最常见(210%)的且在阿比特龙治疗组更常见2%的药物"}, {"probability": {"variance": 0.002347, "average": 0.977236, "min": 0.793685}, "location": {"width": 870, "top": 726, "height": 41, "left": 196}, "words": "不良反应为疲乏、关节肿胀或不适、水肿、潮热、腹泻、呕吐、咳嗽、高血压、呼吸困难、尿"}, {"probability": {"variance": 0.048339, "average": 0.582828, "min": 0.362968}, "location": {"width": 129, "top": 756, "height": 38, "left": 811}, "words": "多"}, {"probability": {"variance": 0.006091, "average": 0.950865, "min": 0.788541}, "location": {"width": 132, "top": 783, "height": 27, "left": 196}, "words": "路感染和挫伤"}, {"probability": {"variance": 0.004288, "average": 0.972556, "min": 0.713865}, "location": {"width": 829, "top": 817, "height": 42, "left": 240}, "words": "这两项随机临床试验报告的最常见(>20%的且在阿比特龙治疗更常见(2%的实验室"}, {"probability": {"variance": 0.001224, "average": 0.984915, "min": 0.786954}, "location": {"width": 871, "top": 864, "height": 41, "left": 199}, "words": "检查异常是贫血、碱性磷酸酶升高、高甘油三酯血症、淋巴细胞减少症、高胆固醇血症、高血"}, {"probability": {"variance": 0.024536, "average": 0.909947, "min": 0.388789}, "location": {"width": 459, "top": 916, "height": 37, "left": 199}, "words": "糖症AST升高、低磷血症、ALT开高和低钾血症"}, {"probability": {"variance": 0.007907, "average": 0.9699, "min": 0.517041}, "location": {"width": 593, "top": 1005, "height": 37, "left": 204}, "words": "研究1x既往接受过多西他赛化疗的转移性去势抵抗性前列腺癌"}, {"probability": {"variance": 0.001801, "average": 0.984277, "min": 0.739255}, "location": {"width": 827, "top": 1046, "height": 42, "left": 246}, "words": "研究1招募了1195例既往接受过多西他赛化疗的转移性去势抵抗性前列腺癌患者。研究"}, {"probability": {"variance": 0.012453, "average": 0.938691, "min": 0.496203}, "location": {"width": 935, "top": 1090, "height": 50, "left": 205}, "words": "规定,没有肝转移的情况下,若AST和/或AT2.5XULN则该患者不能入组。有肝转移的NP"}, {"probability": {"variance": 0.012246, "average": 0.926942, "min": 0.543788}, "location": {"width": 449, "top": 1145, "height": 37, "left": 205}, "words": "者,若AST和/或AL>5XUN也不符合入组条件"}, {"probability": {"variance": 0.04367, "average": 0.681993, "min": 0.448537}, "location": {"width": 95, "top": 1133, "height": 47, "left": 1024}, "words": "称称制"}, {"probability": {"variance": 0.013101, "average": 0.962406, "min": 0.387641}, "location": {"width": 900, "top": 1185, "height": 42, "left": 252}, "words": "表1显示研究中本品治疗组不良反应发生率较安慰剂组增加%的不良反应成需特别关"}, {"probability": {"variance": 0.000201, "average": 0.991315, "min": 0.953154}, "location": {"width": 426, "top": 1240, "height": 32, "left": 209}, "words": "注的不良事件。本品的中位治疗时间是8个月"}, {"probability": {"variance": 0.010731, "average": 0.619359, "min": 0.51577}, "location": {"width": 98, "top": 1199, "height": 99, "left": 1066}, "words": "令以"}, {"probability": {"variance": 0.05122, "average": 0.863799, "min": 0.385386}, "location": {"width": 336, "top": 1289, "height": 28, "left": 210}, "words": "表1研究道中本治疗的不良反应"}, {"probability": {"variance": 0.003388, "average": 0.935102, "min": 0.831772}, "location": {"width": 126, "top": 1333, "height": 24, "left": 630}, "words": "本品泼尼松"}, {"probability": {"variance": 0.000811, "average": 0.982368, "min": 0.916028}, "location": {"width": 146, "top": 1328, "height": 26, "left": 884}, "words": "安慰剂+泼尼松"}, {"probability": {"variance": 0.01343, "average": 0.918778, "min": 0.673309}, "location": {"width": 81, "top": 1371, "height": 22, "left": 652}, "words": "(N=791"}, {"probability": {"variance": 0.004374, "average": 0.959368, "min": 0.84483}, "location": {"width": 56, "top": 1369, "height": 23, "left": 923}, "words": "N=39"}, {"probability": {"variance": 0.003151, "average": 0.970353, "min": 0.845033}, "location": {"width": 120, "top": 1413, "height": 25, "left": 214}, "words": "系统器官分类"}, {"probability": {"variance": 0.027004, "average": 0.927779, "min": 0.427058}, "location": {"width": 475, "top": 1409, "height": 32, "left": 583}, "words": "所有级别3-4级所有级别3-4级"}, {"probability": {"variance": 9e-06, "average": 0.996476, "min": 0.992334}, "location": {"width": 81, "top": 1453, "height": 26, "left": 232}, "words": "不良反应"}, {"probability": {"variance": 0, "average": 0.978023, "min": 0.978023}, "location": {"width": 20, "top": 1454, "height": 22, "left": 619}, "words": "%"}, {"probability": {"variance": 0, "average": 0.999934, "min": 0.999934}, "location": {"width": 20, "top": 1455, "height": 20, "left": 753}, "words": "%"}, {"probability": {"variance": 0, "average": 0.99977, "min": 0.99977}, "location": {"width": 19, "top": 1448, "height": 20, "left": 1016}, "words": "%"}], "language": 3}